These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30986263)

  • 41. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
    Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
    J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins.
    Distelmaier M; Barabasch A; Heil P; Kraemer NA; Isfort P; Keil S; Kuhl CK; Bruners P
    Radiology; 2017 Dec; 285(3):1023-1031. PubMed ID: 28799842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contrast enhanced ultrasound (CEUS) with parametric imaging after irreversible electroporation (IRE) of the prostate to assess the success of prostate cancer treatment.
    Jung EM; Engel M; Wiggermann P; Schicho A; Lerchbaumer M; Stroszczynski C; Fischer T; Wiesinger I
    Clin Hemorheol Microcirc; 2021; 77(3):303-310. PubMed ID: 33337354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation.
    Vroomen LGPH; Scheffer HJ; Melenhorst MCAM; de Jong MC; van den Bergh JE; van Kuijk C; van Delft F; Kazemier G; Meijerink MR
    Eur Radiol; 2017 Jun; 27(6):2521-2531. PubMed ID: 27659702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MRI-TRUS fusion for electrode positioning during irreversible electroporation for treatment of prostate cancer.
    Baur ADJ; Collettini F; Enders J; Maxeiner A; Schreiter V; Stephan C; Gebauer B; Hamm B; Fischer T
    Diagn Interv Radiol; 2017; 23(4):321-325. PubMed ID: 28508759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement: Safety and Efficacy.
    Simmerman E; Chung J; Lawson A; Kruse E
    J Surg Res; 2020 Feb; 246():260-268. PubMed ID: 31610354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art.
    Faiella E; Santucci D; Vertulli D; Vergantino E; Vaccarino F; Perillo G; Beomonte Zobel B; Grasso RF
    J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392571
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer.
    Lantz A; Nordlund P; Falagario U; Jäderling F; Özbek O; Clements M; Discacciati A; Grönberg H; Eklund M; Stricker P; Emberton M; Aly M; Nordström T
    Eur Urol Open Sci; 2023 May; 51():89-94. PubMed ID: 37091033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series.
    Vroomen LGPH; Scheffer HJ; Melenhorst MCAM; van Grieken N; van den Tol MP; Meijerink MR
    Cardiovasc Intervent Radiol; 2017 Oct; 40(10):1631-1640. PubMed ID: 28470395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrent Colorectal Liver Metastases in the Liver Remnant After Major Liver Surgery-IRE as a Salvage Local Treatment When Resection and Thermal Ablation are Unsuitable.
    Hitpass L; Distelmaier M; Neumann UP; Schöning W; Isfort P; Keil S; Kuhl CK; Bruners P; Barabasch A
    Cardiovasc Intervent Radiol; 2022 Feb; 45(2):182-189. PubMed ID: 34757483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol.
    Marra G; Shah TT; D'Agate D; Marquis A; Calleris G; Lunelli L; Filippini C; Oderda M; Gatti M; Valerio M; Sanchez-Salas R; Bossi A; Gomez-Rivas J; Conte F; Deandreis D; Cussenot O; Ricardi U; Gontero P
    Front Surg; 2022; 9():900528. PubMed ID: 35747441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma.
    Marsanic P; Mellano A; Sottile A; De Simone M
    Med Biol Eng Comput; 2017 Jul; 55(7):1123-1127. PubMed ID: 28078482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.
    Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB
    World J Urol; 2017 Jan; 35(1):11-20. PubMed ID: 27147512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection.
    Månsson C; Nilsson A; Nygren P; Karlson BM
    Anticancer Res; 2020 May; 40(5):2771-2775. PubMed ID: 32366423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
    Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.
    Valerio M; Stricker PD; Ahmed HU; Dickinson L; Ponsky L; Shnier R; Allen C; Emberton M
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):343-7. PubMed ID: 25179590
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
    Belfiore MP; Ronza FM; Romano F; Ianniello GP; De Lucia G; Gallo C; Marsicano C; Di Gennaro TL; Belfiore G
    Int J Surg; 2015 Sep; 21 Suppl 1():S34-9. PubMed ID: 26118600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.
    van den Bos W; de Bruin DM; Jurhill RR; Savci-Heijink CD; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna-Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    World J Urol; 2016 May; 34(5):657-64. PubMed ID: 26296371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.
    Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR
    Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Irreversible electroporation for the ablation of liver tumors: are we there yet?
    Charpentier KP
    Arch Surg; 2012 Nov; 147(11):1053-61. PubMed ID: 23165618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.